Beximco Pharmaceuticals has resumed trading of its Global Depository Receipts (GDRs) on the London Stock Exchange (LSE) from June 26, following the withdrawal of a trading suspension. The Dhaka Stock Exchange Brokers’ Association (DBA) confirmed the development on June 27. The company had faced a suspension since January 2 due to delays in publishing audited financial statements for the fiscal year ending June 30, 2025, and subsequent reports.
According to the source, the suspension stemmed from a dispute over the company’s board composition after the Bangladesh Securities and Exchange Commission (BSEC) was restructured under the interim government formed following political changes in 2024. The reconstituted BSEC appointed nine independent directors to Beximco Pharma’s board, a move the company challenged in court. This deadlock delayed financial approvals, triggering the LSE suspension.
After investor appeals and coordination among BSEC, DBA, and company management, Beximco Pharma held a special board meeting on June 23 to approve pending financial statements. The LSE then lifted the suspension, a move the DBA said would strengthen Bangladesh’s international market reputation and investor confidence.
অর্থনৈতিক রিপোর্টার প্রকাশ : ২৭ জুন ২০২৬, ২২: ৪৩ তালিকাচ্যুতির শঙ্কা কাটিয়ে অবশেষে লন্ডন স্টক এক্সচেঞ্জে (এলএসই) লেনদেনে ফিরেছে বেক্সিমকো ফার্মাসিউটিক্যালস। কোম্পানিটির গ্লোবাল ডিপোজিটরি রিসিপ্টসের (জিডিআর) ওপর আরোপিত ট্রেডিং সাসপেনশন প্রত্যাহার করে
The ‘1 Nojor’ media platform is now live in beta, inviting users to explore and provide feedback as we continue to refine the experience.
